- Home
- MYGN vs GSL Comparison
MYGN vs GSL Comparison
Compare MYGN & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- GSL
- Stock Information
- Founded
- MYGN 1991
- GSL 2007
- Country
- MYGN United States
- GSL Greece
- Employees
- MYGN N/A
- GSL N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GSL Marine Transportation
- Sector
- MYGN Health Care
- GSL Consumer Discretionary
- Exchange
- MYGN Nasdaq
- GSL Nasdaq
- Market Cap
- MYGN 744.7M
- GSL 886.8M
- IPO Year
- MYGN 1995
- GSL 2006
- Fundamental
- Price
- MYGN $4.92
- GSL $26.05
- Analyst Decision
- MYGN Hold
- GSL Strong Buy
- Analyst Count
- MYGN 15
- GSL 1
- Target Price
- MYGN $15.14
- GSL $30.00
- AVG Volume (30 Days)
- MYGN 2.1M
- GSL 370.2K
- Earning Date
- MYGN 08-05-2025
- GSL 08-04-2025
- Dividend Yield
- MYGN N/A
- GSL 8.05%
- EPS Growth
- MYGN N/A
- GSL 20.64
- EPS
- MYGN N/A
- GSL 10.54
- Revenue
- MYGN $831,300,000.00
- GSL $715,232,000.00
- Revenue This Year
- MYGN N/A
- GSL $3.22
- Revenue Next Year
- MYGN $6.68
- GSL N/A
- P/E Ratio
- MYGN N/A
- GSL $2.54
- Revenue Growth
- MYGN 7.38
- GSL 3.83
- 52 Week Low
- MYGN $3.81
- GSL $17.73
- 52 Week High
- MYGN $29.30
- GSL $30.19
- Technical
- Relative Strength Index (RSI)
- MYGN 46.03
- GSL 59.71
- Support Level
- MYGN $4.78
- GSL $25.96
- Resistance Level
- MYGN $5.29
- GSL $26.66
- Average True Range (ATR)
- MYGN 0.32
- GSL 0.57
- MACD
- MYGN 0.11
- GSL -0.03
- Stochastic Oscillator
- MYGN 60.98
- GSL 65.35
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.